Trial
NCT03669640
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Schizophrenia, Schizoaffective Disorder
Intervention
RO6889450
Why stopped
This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-12